(28%) lung, 20 (21%) bone, 13 (14%) lymph node, 7 (7%) adrenal gland, 7 brain (7%), and 21 other sites (22%). The most common alterations were VHL (85%), PBRM1 (45%), SETD2 (37%), BAP1 (20%). When analyzing samples by site, metastases to pleura presented with enrichment in BAP1 mutations (P¼0.008), adrenal gland metastases had an enrichment in MED12 mutations (P¼0.005), and NF2 alterations were found to be associated with bone metastases (P¼0.08).
INTRODUCTION AND OBJECTIVES: Unclassified renal cell carcinoma (uRCC) is a rare, aggressive non-clear cell variant recognized by the World Health Organization (WHO) and which has no standard therapy. Currently, there is no consensus on further stratifying uRCC subtypes based on histological findings. We recently reported the findings of a molecular analysis of 62 high-grade primary uRCC from our institution ("discovery cohort") in which we identified recurrent somatic mutations in 29 genes (Chen et al, Nat Comm 2016) . In this study we aim to report the clinical characteristics of the largest series of patients with uRCC and to validate the molecular features using an independent clinical cohort.
METHODS: Tumor samples from primary renal (n¼39) and metastatic sites (n¼20) from 59 patients ("validation cohort") diagnosed with advanced uRCC by expert pathologists were analyzed using targeted next-generation sequencing for somatic alterations. Molecular and clinical characteristics of these samples were compared to the previously reported discovery cohort.
RESULTS: Clinical patient and tumor characteristics of the discovery cohort (n¼62) and the validation cohort (n¼59) are depicted in table 1. The frequently mutated genes in the validation cohort were NF2(27%), SETD2(12%), FH(12%), TP53(10%), TERT(8%), and PIK3CA(8%). NF2and SETD2were the two most frequently mutated genes, consistent with the discovery cohort. Systemic therapy was given to 42 patients. The median follow-up was 19.9 months. Seventeen patients died secondary to disease and one from other causes. Inactivating mutations of NF2or other member of Hippo pathway (27%) accounted for 41% of cancer-specific death, with median survival of 21 months, representing the largest molecular subset of uRCC demonstrating poor outcomes.
CONCLUSIONS: URCC is an aggressive subtype of RCC, with data suggesting loss of NF2to have the worst outcomes. Molecular analysis of our current uRCC validation cohort with more advanced disease reveals similar molecular subsets as in the discovery cohort of primary RCC. These findings open a new opportunity for precision medicine. ; ggt-cre +/-) or activated transposon mutagenesis (3: Onc2 +/-, trpase +/-; ggt-cre +/-) alone. Mice were serial imaged by ultrasound and MRI. All kidneys were then examined grossly and histologically at necropsy after aging.
RESULTS: All mice (N¼5) with both C-Met hyperactivation and transposon activity (1) developed large renal cysts by 6 months. No mice with only C-Met hyper-activation (2; N¼10) or transposon activity (3; N¼10) developed cysts by 6 months. Histological analysis demonstrated fluid filled and hemorrhagic renal cysts without evidence for malignancy.
CONCLUSIONS: C-Met hyperactivation is insufficient to drive renal cyst formation in isolation. Combining M1248T with transposon mutagenesis drove renal cyst formation with 100% penetrance. By mapping transposon insertion sites in cyst-lining epithelial cells in this model, we can now begin to isolate these interacting genes, which may improve our understanding of the molecular mechanisms underlying ARCD.
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